We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Researchers are developing several lines of attack against HIV, all of which show promise in reducing infection rates.

The field of pre-sex HIV prevention is "red-hot cool right now", says Sharon L. Hillier, a gynaecology professor at the University of Pittsburgh's medical school and principal investigator of the Microbicide Trials Network.

Earlier this year a clinical trial showed for the first time that a microbicide gel can help prevention of HIV. With other trials planned for 2011–2012 researchers hope the gel will be on the market by 2013.

But other options may also soon become available. Results from trials on the use of oral pre-exposure prophylaxis, or 'oral prep' for short, are expected to start over the next few months, according to Mitchell Warren, executive director of AVAC, an advocacy group for AIDS prevention. Oral prep involves giving a daily dose of antiretrovirals to people in the high risk groups, such as sex workers.

If the method works, approving the use of such pills would be much faster than approving a new gel, because they have already proved safe and effective in the treatment of HIV/AIDS.

A trial is planned for next year for another method: a vaginal ring containing the antiretroviral drug dapivirine. Dapivirine does not work as a pill as the body fails to absorb the drug, but if used in a ring loaded with the drug it could work in the vaginal tissue.

"The simple truth is: one size does not fit all," says Salim Abdool Karim, epidemiologist at the University of KwaZulu-Natal in South Africa and a leader of the successful microbicide trial. Just as people like to have a choice of birth control methods, they will also like to have a choice of AIDS prevention methods, experts say.

Link to full article in The New York Times